ArticleJCI insight2021
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.The New England journal of medicine · 2026Trial
- Survival analysis in pT1-3 and paracolic lymph-node invasion colorectal cancer: the prognostic role of positive paracolic lymph-node ratio for adjuvant chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Trial
- Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Review
- Article
- Impact of MMR status on preoperative CT-based lymph node overstaging in right-sided colon cancer: a retrospective analysis.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Effect of lymph node dissection numbers after conversion immunochemotherapy on the survival of gastric cancer patients: a multi-center retrospective study.Frontiers in immunology · 2026Observational
- Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects.Frontiers in immunology · 2026Review
- Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study.Cancer immunology, immunotherapy : CII · 2025Article
- Predictive value of combined DCE-MRI perfusion parameters and clinical features nomogram for microsatellite instability in colorectal cancer.Discover oncology · 2025Article
- The Current Status of T Cell Receptor (TCR) Repertoire Analysis in Colorectal Cancer.International journal of molecular sciences · 2025Review
- Preputial and scrotal cutaneous mast cell tumors in dogs show no evidence of inherently higher biologic malignancy.Frontiers in veterinary science · 2025Article
- Balancing oncological control and immune preservation in the immunotherapy era: revisiting lymph node dissection in non-small cell lung cancer.Frontiers in oncology · 2025Review
- Cell Identity and Spatial Distribution of PD-1/PD-L1 Blockade Responders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Phenotypic and spatial heterogeneity of CD8Molecular cancer · 2024Review
- Prognostic significance of negative lymph node count in microsatellite instability-high colorectal cancer.World journal of surgical oncology · 2024Article
- Prognostic and predictive value of examined lymph node count in stage III colorectal cancer: a population based study.World journal of surgical oncology · 2024Article
- Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy.Journal for immunotherapy of cancer · 2024Review
- Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.Frontiers in immunology · 2024Review
- Enlarged tumour-draining lymph node with immune-activated profile predict favourable survival in non-metastatic colorectal cancer.British journal of cancer · 2024Article
- Preoperative contrast-enhanced CT imaging and clinicopathological characteristics analysis of mismatch repair-deficient colorectal cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with colorectal cancers (CRCs) generally exhibit improved survival through intensive lymph node (LN) dissection. However, recent progress in cancer immunotherapy revisits the potential importance of regional LNs, where T cells are primed to attack tumor cells. To elucidate the role of regional LN, we investigated the immunological status of nonmetastatic regional LN lymphocytes (LNLs) in comparison with those of the tumor microenvironment (tumor-infiltrating lymphocytes; TILs) using flow cytometry and next-generation sequencing. LNLs comprised an intermediate level of the effector T cell population between peripheral blood lymphocytes (PBLs) and TILs. Significant overlap of the T cell receptor (TCR) repertoire was observed in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) CRCs with high tumor mutation burden (TMB), although limited TCRs were shared between nonmetastatic LNs and primary tumors in microsatellite stable/MMR proficient (MSS/pMMR) CRC patients with low TMB. In line with the overlap of the TCR repertoire, an excessive LN dissection did not provide a positive impact on long-term prognosis in our MSI-H/dMMR CRC cohort (n = 130). We propose that regional LNs play an important role in antitumor immunity, particularly in MSI-H/dMMR CRCs with high TMB, requiring care to be taken regarding excessive nonmetastatic LN dissection in MSI-H/dMMR CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.